NanoNewron and its Research to Advance the Treatment of Alzheimer's Disease are Featured by Rutgers University Newsletters and on Rutgers Today [Yahoo! Finance]
SCYNEXIS, Inc. (SCYX)
Last scynexis, inc. earnings: 11/12 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.scynexis.com/investor-relations
Company Research
Source: Yahoo! Finance
developing innovative, humanized biologics that cross the blood-brain barrier (BBB) to treat central nervous system (CNS) neurodegenerative diseases, announced today that Rutgers, the State University of New Jersey, is featuring the Company's pipeline and research activities on their newsletters and on Rutgers' Today ( https://go.rutgers.edu/NanoNewron The article highlights the potentially game-changing approach of the Company towards treating Alzheimer's Disease, based on technology developed at Rutgers by Dr. Luciano D'Adamio, PhD, MD, New Jersey Medical School professor of Pharmacology, Physiology & Neuroscience and the Herbert and Jacqueline Klein Endowed Chair in Alzheimer's Disease and Neurodegeneration Research at the Rutgers Brain Health Institute “There is still a dire need for more effective treatments for Alzheimer's Disease,” said Marco Taglietti, MD, Chief Executive Officer of NanoNewron. “Despite decades of research, the current treatments only offer temporary impro
Show less
Read more
Impact Snapshot
Event Time:
SCYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCYX alerts
High impacting SCYNEXIS, Inc. news events
Weekly update
A roundup of the hottest topics
SCYX
News
- SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSKGlobeNewswire
- Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal InfectionsGlobeNewswire
- SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
SCYX
Earnings
- 11/5/25 - Beat
SCYX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- 11/5/25 - Form 10-Q
- SCYX's page on the SEC website